NASDAQ:ALRN Aileron Therapeutics (ALRN) Stock Price, News & Analysis → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Free ALRN Stock Alerts $5.06 +0.13 (+2.64%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$4.84▼$5.4350-Day Range$4.25▼$7.0952-Week Range$1.01▼$7.42Volume80,550 shsAverage Volume64,769 shsMarket Capitalization$85.87 millionP/E RatioN/ADividend YieldN/APrice Target$19.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Aileron Therapeutics alerts: Email Address Aileron Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside276.2% Upside$19.00 Price TargetShort InterestHealthy0.31% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.62) to ($1.81) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.32 out of 5 starsMedical Sector581st out of 907 stocksPharmaceutical Preparations Industry263rd out of 422 stocks 3.5 Analyst's Opinion Consensus RatingAileron Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAileron Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.31% of the float of Aileron Therapeutics has been sold short.Short Interest Ratio / Days to CoverAileron Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aileron Therapeutics has recently increased by 22.95%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAileron Therapeutics does not currently pay a dividend.Dividend GrowthAileron Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALRN. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Aileron Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for ALRN on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows3 people have added Aileron Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aileron Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.57% of the stock of Aileron Therapeutics is held by insiders.Percentage Held by Institutions90.89% of the stock of Aileron Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Aileron Therapeutics are expected to decrease in the coming year, from ($0.62) to ($1.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aileron Therapeutics is -1.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aileron Therapeutics is -1.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAileron Therapeutics has a P/B Ratio of 3.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. About Aileron Therapeutics Stock (NASDAQ:ALRN)Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.Read More ALRN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALRN Stock News HeadlinesApril 20, 2024 | americanbankingnews.comAileron Therapeutics (NASDAQ:ALRN) PT Raised to $19.00 at LADENBURG THALM/SH SHApril 16, 2024 | investorplace.comALRN Stock Earnings: Aileron Therapeutics Reported Results for Q4 2023April 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.April 16, 2024 | finanznachrichten.deAileron Therapeutics, Inc.: Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateApril 16, 2024 | americanbankingnews.comAileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest UpdateApril 15, 2024 | globenewswire.comAileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 12, 2024 | markets.businessinsider.comAileron Therapeutics CEO Manuel Aivado Steps Down; Names Brian Windsor ReplacementMarch 12, 2024 | globenewswire.comAileron Therapeutics Announces CEO TransitionApril 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.February 15, 2024 | finance.yahoo.comAileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader EventFebruary 15, 2024 | globenewswire.comAileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader EventFebruary 1, 2024 | finance.yahoo.comAileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024January 30, 2024 | msn.comAileron Therapeutics Announces Director Nomination DetailsJanuary 30, 2024 | msn.comAileron Therapeutics Announces 2024 Annual Meeting PlansDecember 27, 2023 | benzinga.comAileron Therapeutics Stock (NASDAQ:ALRN) Dividends: History, Yield and DatesDecember 15, 2023 | msn.comU.S. shares higher at close of trade; Dow Jones Industrial Average up 0.43%December 1, 2023 | realmoney.thestreet.comAileron Therapeutics upgraded to Buy at Ladenburg after Lung Therapeutics dealDecember 1, 2023 | realmoney.thestreet.comAileron Therapeutics upgraded to Buy from Neutral at LadenburgNovember 5, 2023 | benzinga.comAileron Therapeutics Director Awarded $6K Worth of Stock OptionsNovember 1, 2023 | msn.comAileron gains after all-stock deal to acquire Lung TherapeuticsOctober 31, 2023 | finance.yahoo.comAileron Therapeutics Announces Acquisition of Lung TherapeuticsApril 4, 2023 | finance.yahoo.comBears are Losing Control Over Aileron Therapeutics, Inc. (ALRN), Here's Why It's a 'Buy' NowMarch 22, 2023 | finance.yahoo.comAileron Therapeutics, Inc. (ALRN)March 14, 2023 | finance.yahoo.comAileron Therapeutics, Inc. (ALRN) Could Find a Support Soon, Here's Why You Should Buy the Stock NowMarch 3, 2023 | msn.comLooking Into Aileron Therapeutics's Recent Short InterestFebruary 23, 2023 | markets.businessinsider.comJonesTrading Keeps Their Hold Rating on Aileron Therapeutics (ALRN)February 22, 2023 | finance.yahoo.comCancer drugmaker down to 3 employees after trial failureSee More Headlines Receive ALRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aileron Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/15/2024Today4/25/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ALRN CUSIPN/A CIK1420565 Webwww.aileronrx.com Phone(617) 995-0900FaxN/AEmployees6Year FoundedN/APrice Target and Rating Average Stock Price Target$19.00 High Stock Price Target$19.00 Low Stock Price Target$19.00 Potential Upside/Downside+274.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($3.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,730,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-130.32% Return on Assets-39.23% Debt Debt-to-Equity RatioN/A Current Ratio4.17 Quick Ratio4.17 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.41 per share Price / Book3.60Miscellaneous Outstanding Shares16,970,000Free Float16,028,000Market Cap$86.04 million OptionableNot Optionable Beta2.22 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. James Brian Windsor Ph.D. (Age 57)CEO & Director Comp: $511.55kMr. Charles T. Garner (Age 48)Principal Financial & Acconting Officer Key CompetitorsInflaRxNASDAQ:IFRXOncolytics BiotechNASDAQ:ONCYAffimedNASDAQ:AFMDLeap TherapeuticsNASDAQ:LPTXMarinus PharmaceuticalsNASDAQ:MRNSView All CompetitorsInsiders & InstitutionsTexas Capital Bank Wealth Management Services IncBought 15,773 shares on 2/8/2024Ownership: 0.323%Sigma Planning CorpBought 16,580 shares on 2/1/2024Ownership: 0.339%James Brian WindsorBought 225 shares on 12/15/2023Total: $758.25 ($3.37/share)James Brian WindsorBought 5,076 shares on 11/20/2023Total: $9,999.72 ($1.97/share)View All Insider TransactionsView All Institutional Transactions ALRN Stock Analysis - Frequently Asked Questions Should I buy or sell Aileron Therapeutics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aileron Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ALRN shares. View ALRN analyst ratings or view top-rated stocks. What is Aileron Therapeutics' stock price target for 2024? 1 Wall Street analysts have issued 1-year price objectives for Aileron Therapeutics' shares. Their ALRN share price targets range from $19.00 to $19.00. On average, they predict the company's stock price to reach $19.00 in the next twelve months. This suggests a possible upside of 276.2% from the stock's current price. View analysts price targets for ALRN or view top-rated stocks among Wall Street analysts. How have ALRN shares performed in 2024? Aileron Therapeutics' stock was trading at $3.05 at the beginning of the year. Since then, ALRN stock has increased by 65.6% and is now trading at $5.05. View the best growth stocks for 2024 here. Are investors shorting Aileron Therapeutics? Aileron Therapeutics saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 43,400 shares, an increase of 22.9% from the March 31st total of 35,300 shares. Based on an average daily trading volume, of 65,900 shares, the days-to-cover ratio is presently 0.7 days. Approximately 0.3% of the shares of the company are sold short. View Aileron Therapeutics' Short Interest. When is Aileron Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our ALRN earnings forecast. How were Aileron Therapeutics' earnings last quarter? Aileron Therapeutics, Inc. (NASDAQ:ALRN) issued its quarterly earnings data on Monday, April, 15th. The company reported ($1.54) earnings per share for the quarter. When did Aileron Therapeutics' stock split? Aileron Therapeutics's stock reverse split before market open on Thursday, November 10th 2022. The 1-20 reverse split was announced on Thursday, November 10th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 10th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Aileron Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aileron Therapeutics investors own include Portola Pharmaceuticals (PTLA), Acasti Pharma (ACST), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Allena Pharmaceuticals (ALNA), OPKO Health (OPK), Amarin (AMRN), Aldeyra Therapeutics (ALDX), Lexicon Pharmaceuticals (LXRX) and Nabriva Therapeutics (NBRV). When did Aileron Therapeutics IPO? Aileron Therapeutics (ALRN) raised $61 million in an initial public offering on Thursday, June 29th 2017. The company issued 3,800,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers. How do I buy shares of Aileron Therapeutics? Shares of ALRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ALRN) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsYour Money is Not SafeAmerican AlternativeThe AI stock to buy right nowStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aileron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
